THE SCIENCE IS UNSETTLED: Too little Vitamin D may increase risk of aggressive prostate cancer. Plus: Vitamin D may prevent prostate tumor growth. But: Highest serum levels of Vitamin D linked to increased prostate cancer risk.
Aiming to increase treatment options for prostate cancer patients who have an early relapse, investigators from a multi-institutional cooperative group - including Rutgers Cancer Institute of New Jersey - have demonstrated that a vaccine therapy that stimulates the body's own immune defenses can be given safely and earlier in the course of prostate cancer progression.
The cause of prostate cancer may be linked to Parkinson’s disease through a common enzyme family called sirtuins. Finding an enzyme that regulates this process could provide excellent new prevention approaches for this common malignancy, researchers say. Sirtuin enzymes have been implicated in neurodegeneration, obesity, heart disease, and cancer.
I had just started the sexual health clinic at Massachusetts General Hospital (MGH) when I was approached to meet with a group of prostate cancer survivors. I was hesitant at first — my interests were in female cancer survivors who had experienced sexual dysfunction. This was partly because I had assumed men had an easier […]
When cancer is diagnosed, the grade of its malignancy is a central concern for both patients and their physicians. This value is used to determine how intensively and how radically the cancer must be treated. Particularly in the case of prostate cancer, the disease can take widely varying courses in different patients. Show More Summary
Ralph Lawler had never let the flu or even prostate cancer stop him from calling a Clippers game in his 36 seasons as the team’s broadcaster, and he didn’t intend the streak to stop Saturday.
Researchers have completed a critical step in the journey from a basic science discovery in the lab to a potential clinical application by showing an experimental agent prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. Show More Summary
WASHINGTON -- Researchers at Georgetown Lombardi Comprehensive Cancer Center have completed a critical step in the journey from a basic science discovery in the lab to a potential clinical application, showing that an experimental agent prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. read more
Gerry Brooks, anchor at NBC-owned WVIT in Hartford, waited until after the November sweeps to reveal he’d be off the air until January because of surgery for prostate cancer. As Brooks told the Hartford Courant‘s MaryEllen Fillo, heShow More Summary
From MedPage Today: Men on ADT Skipping Out on Bisphosphonates. Few men in Canada receiving androgen deprivation therapy (ADT) for prostate cancer have simultaneous bisphosphonate treatment to prevent fractures. What Every ED Should Have. The emergency department (ED) is one of the highest risk areas of any institution. Both the fast-paced environment and high patient volume […]
A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. Results appear in European Urology.
SALT LAKE CITY, Utah, Dec. 2, 2014 - Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology (SUO) Annual Meeting being held tomorrow in Rockville, Md. Show More Summary
In the first study to rigorously address prostate cancer treatment trends by life expectancy in a large, nationally representative sample, UCLA researchers found that more than half of prostate cancer patients 66 years and older have...Show More Summary
Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread.
(PHILADELPHIA) - Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers...Show More Summary
The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread
AnnaLynne McCord works the red carpet in her low-back dress at the Associates for Breast and Prostate Cancer Studios 2014 Talk of The Town Black Tie Gala held at The Beverly Hilton Hotel on Saturday (November 22) in Beverly Hills, Calif. The 27-year-old actress was joined at the event by Nicky Whelan, Brandon T. Jackson, [...]
New York, NY, November 25, 2014 - Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data. Show More Summary